|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9050307||VISTAPHARM||Method for the preparation of a levothyroxine solution|| |
(7 years from now)
Thyquidity is owned by Vistapharm.
Thyquidity contains Levothyroxine Sodium.
Thyquidity has a total of 1 drug patent out of which 0 drug patents have expired.
Thyquidity was authorised for market use on 30 November, 2020.
Thyquidity is available in solution;oral dosage forms.
The generics of Thyquidity are possible to be released after 06 August, 2031.
Market Authorisation Date: 30 November, 2020
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic